Towards a Quantum Steganographic Capacity of Lossy Bosonic Channels

Quantum steganography is the extension of steganography to the quantum setting, wherein a quantum protocol (e.g.: a quantum error-correcting code) is used to hide classical or quantum information. Because of the unique nature of quantum states and channels, quantum steganography can be stronger than classical steganography. A lot of effort has been devoted to characterizing how much information can be embedded into various quantum channels with or without noise, and recently, several quantum steganography protocols have been developed and analyzed that improve on earlier work by exploiting a concept known in information theory as channel resolvability. This paper first provides a concise background survey of specific topics from relevant disciplines in classical as well as quantum information theory, and then presents a formulation of the problem concerning the characterization of the steganographic capacity for a specific type of quantum channel called the lossy bosonic channel.Undergraduat

Implementation of Super Resolution Techniques in Geospatial Satellite Imagery

The potential for more precise land cover classifications and pattern analysis is provided by technological advancements and the growing accessibility of high-resolution satellite images, which might significantly improve the detection and quantification of land cover change for conservation.  A group of methods known as "super-resolution imaging" use generative modelling to increase the resolution of an imaging system. Super-Resolution Imaging, which falls under the category of sophisticated computer vision and image processing, has a variety of practical uses, including astronomical imaging, surveillance and security, medical imaging, and satellite imaging. As computer vision is where deep learning algorithms for super-resolution first appeared, they were mostly created on RGB images in 8-bit colour depth, where the sensor and camera are separated by a few meters. But no evaluation of these methods has been done

Case report: Successful treatment of recurrent chordoma and bilateral pulmonary metastases following an 11-year disease-free period

AbstractINTRODUCTIONChordomas are rare but aggressive tumors due to local recurrence and distant metastases. They originate commonly in the sphenooccipital and sacrococcygeal regions, and metastasize to the lungs, bone, skin, liver, and lymph nodes. They occur more frequently in men and people over the age of 40.PRESENTATION OF CASEA 28 year-old female presented with sacrococcygeal chordoma for which she received wide local excision and adjuvant radiation therapy. She enjoyed an unusual disease-free survival for 11 years until a routine surveillance scan of the pelvis identified local recurrence. Further work up revealed bilateral pulmonary metastases. She underwent local excision of the recurrent tumor and video-assisted thoracoscopic (VATS) wedge resection of pulmonary metastases. She also received adjuvant radiation therapy to the recurrent resection bed. Two years later, she remains free of disease and symptoms.DISCUSSIONChordomas are commonly insensitive to chemotherapy and radiation, making surgery the most successful therapeutic modality. However, there are few guidelines on the surveillance and treatment of recurrent chordoma. We report success with aggressive surgical resection of recurrence and metastasis as well as adjuvant radiation therapy.CONCLUSIONThe prolonged survival of our patient underscores the importance of (1) aggressive surgical resection of chordoma, whether primary, recurrent, or metastatic, with adjuvant radiation therapy, (2) minimization of surgical seeding of tumor, and (3) diligent cancer surveillance

Drosophila Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions

Turnover of endosomal PI(3)P by mtm maintains endolysosomal homeostasis and cortical remodeling in Drosophila hemocytes during migration

Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy

Importance: It is a global challenge to provide regular retinal screening for all people with diabetes to detect sight-threatening diabetic retinopathy (STDR). Objective: To determine if circulating biomarkers could be used to prioritize people with type 2 diabetes for retinal screening to detect STDR. Design, Setting, and Participants: This cross-sectional study collected data from October 22, 2018, to December 31, 2021. All laboratory staff were masked to the clinical diagnosis, assigned a study cohort, and provided with the database containing the clinical data. This was a multicenter study conducted in parallel in 3 outpatient ophthalmology clinics in the UK and 2 centers in India. Adults 40 years and older were categorized into 4 groups: (1) no history of diabetes, (2) type 2 diabetes of at least 5 years' duration with no evidence of DR, (3) nonproliferative DR with diabetic macular edema (DME), or (4) proliferative DR. STDR comprised groups 3 and 4. Exposures: Thirteen previously verified biomarkers were measured using enzyme-linked immunosorbent assay. Main Outcomes and Measures: Severity of DR and presence of DME were diagnosed using fundus photographs and optical coherence tomography. Weighted logistic regression and receiver operating characteristic curve analysis (ROC) were performed to identify biomarkers that discriminate STDR from no DR beyond the standard clinical parameters of age, disease duration, ethnicity (in the UK) and hemoglobin A1c. Results: A total of 538 participants (mean [SD] age, 60.8 [9.8] years; 319 men [59.3%]) were recruited into the study. A total of 264 participants (49.1%) were from India (group 1, 54 [20.5%]; group 2, 53 [20.1%]; group 3, 52 [19.7%]; group 4, 105 [39.8%]), and 274 participants (50.9%) were from the UK (group 1, 50 [18.2%]; group 2, 70 [25.5%]; group 3, 55 [20.1%]; group 4, 99 [36.1%]). ROC analysis (no DR vs STDR) showed that in addition to age, disease duration, ethnicity (in the UK) and hemoglobin A1c, inclusion of cystatin C had near-acceptable discrimination power in both countries (area under the receiver operating characteristic curve [AUC], 0.779; 95% CI, 0.700-0.857 in 215 patients in the UK with complete data; AUC, 0.696; 95% CI, 0.602-0.791 in 208 patients in India with complete data). Conclusions and Relevance: Results of this cross-sectional study suggest that serum cystatin C had good discrimination power in the UK and India. Circulating cystatin-C levels may be considered as a test to identify those who require prioritization for retinal screening for STDR

Challenges to Reporting the Global Trends in the Epidemiology of ICU-Treated Sepsis and Septic Shock

Purpose of Review: It is widely believed that the epidemiology of sepsis and septic shock treated in the intensive care unit (ICU) is changing. However, quantifying changes in occurrence and outcomes of ICU-treated sepsis and septic shock are challenged by a number of factors related to study designs as well as varied local resource availability and practices. The authors conducted a structured literature review to examine contemporary studies reporting trends in the prevalence, incidence and case-fatality rates of ICU-treated sepsis and septic shock around the world and further attempted to extrapolate the recent epidemiological trends. Recent Findings: During 2015–2020, 13 observational studies with heterogenous methodologies were published from predominantly high-income countries that examined selected cohorts with ICU-treated sepsis, sepsis with end-organ failure (previously known as severe sepsis) and septic shock. The prevalence of sepsis and sepsis-related diagnoses ranged widely from 4.7–42.2% of ICU admissions. The population incidence varied widely between 88 and 370 cases per 100,000 for sepsis and 19 and 79 cases per 100,000 for septic shock. Mean case-fatality rates (deaths per number of cases, %) reported primarily as in-hospital deaths reduced from approximately 40–50% reported in previous years, to 30–40% in the past 5 years. There was a lack of recent studies specifically examining mortality at the population level. Summary: Contemporary studies have observed wide variation in prevalence and incidence of sepsis and septic shock along with reports of static or decreasing case-fatality rates, but we are not able to make generalised commentary on global trends from the results of existing studies. Further data from ICUs in low-income and middle-income countries is needed, and well-designed, consistent population-based studies are required in order to establish whether the burden of sepsis and septic shock is changing.</p

A Brief Review of Bolus Osmotherapy Use for Managing Severe Traumatic Brain Injuries in the Pre-Hospital and Emergency Department Settings

Background: Severe traumatic brain injury (TBI) management begins in the pre-hospital setting, but clinicians are left with limited options for stabilisation during retrieval due to time and space constraints, as well as a lack of access to monitoring equipment. Bolus osmotherapy with hypertonic substances is commonly utilised as a temporising measure for life-threatening brain herniation, but much contention persists around its use, largely stemming from a limited evidence base. Method: The authors conducted a brief review of hypertonic substance use in patients with TBI, with a particular focus on studies involving the pre-hospital and emergency department (ED) settings. We aimed to report pragmatic information useful for clinicians involved in the early management of this patient group. Results: We reviewed the literature around the pharmacology of bolus osmotherapy, commercially available agents, potential pitfalls, supporting evidence and guideline recommendations. We further reviewed what the ideal agent is, when it should be administered, dosing and treatment endpoints and/or whether it confers meaningful long-term outcome benefits. Conclusions: There is a limited evidence-based argument in support of the implementation of bolus osmotherapy in the pre-hospital or ED settings for patients who sustain a TBI. However, decades’ worth of positive clinician experiences with osmotherapy for TBI will likely continue to drive its on-going use. Choices regarding osmotherapy will likely continue to be led by local policies, individual patient characteristics and clinician preferences

A Brief Review of Bolus Osmotherapy Use for Managing Severe Traumatic Brain Injuries in the Pre-Hospital and Emergency Department Settings

Background: Severe traumatic brain injury (TBI) management begins in the pre-hospital setting, but clinicians are left with limited options for stabilisation during retrieval due to time and space constraints, as well as a lack of access to monitoring equipment. Bolus osmotherapy with hypertonic substances is commonly utilised as a temporising measure for life-threatening brain herniation, but much contention persists around its use, largely stemming from a limited evidence base. Method: The authors conducted a brief review of hypertonic substance use in patients with TBI, with a particular focus on studies involving the pre-hospital and emergency department (ED) settings. We aimed to report pragmatic information useful for clinicians involved in the early management of this patient group. Results: We reviewed the literature around the pharmacology of bolus osmotherapy, commercially available agents, potential pitfalls, supporting evidence and guideline recommendations. We further reviewed what the ideal agent is, when it should be administered, dosing and treatment endpoints and/or whether it confers meaningful long-term outcome benefits. Conclusions: There is a limited evidence-based argument in support of the implementation of bolus osmotherapy in the pre-hospital or ED settings for patients who sustain a TBI. However, decades&rsquo; worth of positive clinician experiences with osmotherapy for TBI will likely continue to drive its on-going use. Choices regarding osmotherapy will likely continue to be led by local policies, individual patient characteristics and clinician preferences